Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The University of Texas M D Anderson Cancer Center (MD Anderson) and Henry M Jackson Foundation for the Advancement of Military Medicine (HJF) have given license to RXi Pharmaceuticals for developing and commercializing Folate Binding Protein-E39 (FBP) targeted vaccine for gynecological cancers.
Subscribe to our email newsletter
The FBP vaccine is a composition of E39 peptide combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF).
RXi Pharma president and CEO Mark Ahn said licensing FBP which is already IND- and IRB- approved, and ready to commence two Phase 1 clinical trials in ovarian/endometrial and breast cancers.
"We anticipate initiation of clinical trials this year and are excited about exploring the promising potential of the FBP vaccine in critical areas of unmet medical need," Ahn said.